Skip to main content
Erschienen in: Journal of Gastroenterology 1/2021

07.11.2020 | Original Article—Alimentary Tract

Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing

verfasst von: Gemma Ibáñez-Sanz, Núria Milà, Luisa C. de la Peña-Negro, Montse Garcia, Carmen Vidal, Lorena Rodríguez-Alonso, Gemma Binefa, Francisco Rodríguez-Moranta, Victor Moreno

Erschienen in: Journal of Gastroenterology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

False-positivity rates in faecal immunochemical test (FIT) can be affected by drug exposure. We aimed to assess the association between proton pump inhibitors (PPI) consumption and false positive (FP) results in a colorectal cancer (CRC) screening programme using electronic prescription records.

Methods

A retrospective cohort study within a population-based screening program for CRC from 2010 to 2016 was performed. Participants with a conclusive FIT result and with prescription electronic data were included. An FP result was defined as having a positive FIT (≥ 20 µg haemoglobin/g faeces) and a follow-up colonoscopy without intermediate or high-risk lesions or CRC. Screening data were anonymously linked to the public data analysis program for health research and innovation (PADRIS) database that recorded patient diseases history and reimbursed medication. PPI exposure was defined as having retrieved at least one dispensation of PPI three months prior to the FIT.

Results

A total of 89,199 tests (of 46,783 participants) were analysed, 4824 (5.4%) tested positive and the proportion of FP was 53.5%. Overall, 17,544 participants (19.7%) were PPI users prior to FIT performance. PPI exposure increased the probability of obtaining an FP FIT result from 50.4 to 63.3% (adjusted OR 1.39; 95% CI 1.18–1.65). Nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, antibiotics, and laxatives were also associated with an FP result. The effect of PPI was independent and showed a synergistic interaction with nonsteroidal anti-inflammatory drugs.

Conclusion

PPIs increase FIT positivity at the expense of FP results. The recommendation to avoid their use before FIT performance could reduce up to 3% of colonoscopies and 9% of FP results.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC Perspective on colorectal cancer screening. N Eng J Med. 2018;378:1734–40. Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC Perspective on colorectal cancer screening. N Eng J Med. 2018;378:1734–40.
2.
Zurück zum Zitat Zorzi M, Fedeli U, Schievano E, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.PubMed Zorzi M, Fedeli U, Schievano E, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.PubMed
3.
Zurück zum Zitat Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147:1317–26.PubMed Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147:1317–26.PubMed
4.
Zurück zum Zitat van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.PubMed van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.PubMed
5.
Zurück zum Zitat Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217–37.e3. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217–37.e3.
6.
Zurück zum Zitat Ponti A, Anttila A, Ronco G, et al. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening (second report). Brussels: European Comission; 2017. Ponti A, Anttila A, Ronco G, et al. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening (second report). Brussels: European Comission; 2017.
7.
Zurück zum Zitat de Klerk CM, Vendrig LM, Bossuyt PM, et al. Participant-Related risk factors for false-positive and false-negative fecal immunochemical tests in colorectal cancer screening: systematic review and meta-analysis. Am J Gastroenterol. 2018;113:1778–87.PubMedPubMedCentral de Klerk CM, Vendrig LM, Bossuyt PM, et al. Participant-Related risk factors for false-positive and false-negative fecal immunochemical tests in colorectal cancer screening: systematic review and meta-analysis. Am J Gastroenterol. 2018;113:1778–87.PubMedPubMedCentral
8.
Zurück zum Zitat Vermeer NC, Snijders HS, Holman FA, et al. Colorectal cancer screening: systematic review of screen-related morbidity and mortality. Cancer Treat Rev. 2017;54:87–98.PubMed Vermeer NC, Snijders HS, Holman FA, et al. Colorectal cancer screening: systematic review of screen-related morbidity and mortality. Cancer Treat Rev. 2017;54:87–98.PubMed
9.
Zurück zum Zitat Laing SS, Bogart A, Chubak J, et al. Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomark Prev. 2014;23:154–9. Laing SS, Bogart A, Chubak J, et al. Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomark Prev. 2014;23:154–9.
10.
Zurück zum Zitat Nieuwenburg SAV, Vuik FER, Kruip M, et al. Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis. Gut. 2019;68:866–72.PubMed Nieuwenburg SAV, Vuik FER, Kruip M, et al. Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis. Gut. 2019;68:866–72.PubMed
11.
Zurück zum Zitat Ibanez-Sanz G, Garcia M, Rodriguez-Moranta F, et al. Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening. Dig and Liver Dise. 2016;48:1249–54. Ibanez-Sanz G, Garcia M, Rodriguez-Moranta F, et al. Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening. Dig and Liver Dise. 2016;48:1249–54.
12.
Zurück zum Zitat Rodriguez-Alonso L, Rodriguez-Moranta F, Arajol C, et al. Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients. PLoS ONE. 2018;13:e0203359.PubMedPubMedCentral Rodriguez-Alonso L, Rodriguez-Moranta F, Arajol C, et al. Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients. PLoS ONE. 2018;13:e0203359.PubMedPubMedCentral
13.
Zurück zum Zitat Peris M, Espinas JA, Munoz L, et al. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007;14:81–6.PubMed Peris M, Espinas JA, Munoz L, et al. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007;14:81–6.PubMed
14.
Zurück zum Zitat Binefa G, Garcia M, Mila N, et al. Colorectal Cancer Screening Programme in Spain: results of key performance indicators after five rounds (2000–2012). Sci Rep. 2016;6:19532.PubMedPubMedCentral Binefa G, Garcia M, Mila N, et al. Colorectal Cancer Screening Programme in Spain: results of key performance indicators after five rounds (2000–2012). Sci Rep. 2016;6:19532.PubMedPubMedCentral
15.
Zurück zum Zitat Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Colonoscopic surveillance following adenoma removal. Endoscopy. 2012;44(Suppl 3):SE151–63.PubMed Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Colonoscopic surveillance following adenoma removal. Endoscopy. 2012;44(Suppl 3):SE151–63.PubMed
17.
Zurück zum Zitat Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut. 2015;64:1257–67.PubMed Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut. 2015;64:1257–67.PubMed
18.
Zurück zum Zitat Rutter MD, Beintaris I, Valori R, et al. World endoscopy organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology. 2018;155:909–25.PubMed Rutter MD, Beintaris I, Valori R, et al. World endoscopy organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology. 2018;155:909–25.PubMed
19.
Zurück zum Zitat Bernal-Delgado EE, Martos C, Martinez N, et al. Is hospital discharge administrative data an appropriate source of information for cancer registries purposes? Some insights from four Spanish registries. BMC Health Serv Res. 2010;10:9.PubMed Bernal-Delgado EE, Martos C, Martinez N, et al. Is hospital discharge administrative data an appropriate source of information for cancer registries purposes? Some insights from four Spanish registries. BMC Health Serv Res. 2010;10:9.PubMed
20.
Zurück zum Zitat Betes M, Munoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98:2648–54.PubMed Betes M, Munoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98:2648–54.PubMed
21.
Zurück zum Zitat Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.PubMed Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.PubMed
22.
Zurück zum Zitat van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Risk of oral and upper gastrointestinal cancers in persons with positive results from a fecal immunochemical test in a colorectal cancer screening program. Clin Gastroenterol Hepatol. 2018;16:1237–43.e2. van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Risk of oral and upper gastrointestinal cancers in persons with positive results from a fecal immunochemical test in a colorectal cancer screening program. Clin Gastroenterol Hepatol. 2018;16:1237–43.e2.
23.
Zurück zum Zitat Le Bastard Q, Al-Ghalith GA, Gregoire M, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther. 2018;47:332–45.PubMed Le Bastard Q, Al-Ghalith GA, Gregoire M, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther. 2018;47:332–45.PubMed
24.
Zurück zum Zitat Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56.PubMed Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56.PubMed
25.
Zurück zum Zitat Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8.PubMed Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8.PubMed
26.
Zurück zum Zitat Reveles KR, Ryan CN, Chan L, et al. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut. 2018;67:1369–70.PubMed Reveles KR, Ryan CN, Chan L, et al. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut. 2018;67:1369–70.PubMed
27.
Zurück zum Zitat Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–22.e1-5.PubMed Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–22.e1-5.PubMed
28.
Zurück zum Zitat Endo H, Sakai E, Taniguchi L, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014;80:826–34.PubMed Endo H, Sakai E, Taniguchi L, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014;80:826–34.PubMed
29.
Zurück zum Zitat Blackler RW, De Palma G, Manko A, et al. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol. 2015;308:G994-1003.PubMed Blackler RW, De Palma G, Manko A, et al. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol. 2015;308:G994-1003.PubMed
30.
Zurück zum Zitat Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809–15.e1. Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809–15.e1.
31.
Zurück zum Zitat Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95:22–8.PubMed Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95:22–8.PubMed
32.
Zurück zum Zitat Fujimori S, Takahashi Y, Tatsuguchi A, et al. Omeprazole increased small intestinal mucosal injury in two of six disease-free cases evaluated by capsule endoscopy. Dig Endosc. 2014;26:676–9.PubMed Fujimori S, Takahashi Y, Tatsuguchi A, et al. Omeprazole increased small intestinal mucosal injury in two of six disease-free cases evaluated by capsule endoscopy. Dig Endosc. 2014;26:676–9.PubMed
33.
Zurück zum Zitat Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894–905.PubMed Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894–905.PubMed
34.
Zurück zum Zitat Mortensen B, Murphy C, O'Grady J, et al. Bifidobacterium breve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers. Gastroenterology. 2019;157:637–46.e4.PubMed Mortensen B, Murphy C, O'Grady J, et al. Bifidobacterium breve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers. Gastroenterology. 2019;157:637–46.e4.PubMed
35.
Zurück zum Zitat Scarpignato C, Dolak W, Lanas A, et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans. Gastroenterology. 2017;152:980–2.e3. Scarpignato C, Dolak W, Lanas A, et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans. Gastroenterology. 2017;152:980–2.e3.
36.
Zurück zum Zitat Gamage H, Tetu SG, Chong RWW, et al. Fiber supplements derived from sugarcane stem, wheat dextrin and psyllium husk have different in vitro effects on the human gut microbiota. Frontiers in microbiology. 2018;9:1618.PubMedPubMedCentral Gamage H, Tetu SG, Chong RWW, et al. Fiber supplements derived from sugarcane stem, wheat dextrin and psyllium husk have different in vitro effects on the human gut microbiota. Frontiers in microbiology. 2018;9:1618.PubMedPubMedCentral
37.
Zurück zum Zitat Llewellyn SR, Britton GJ, Contijoch EJ, et al. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in Mice. Gastroenterology. 2018;154:1037–46.e2. Llewellyn SR, Britton GJ, Contijoch EJ, et al. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in Mice. Gastroenterology. 2018;154:1037–46.e2.
38.
Zurück zum Zitat Jalanka J, Major G, Murray K, et al. The Effect of psyllium husk on intestinal microbiota in constipated patients and healthy controls. Int J Mol Sci. 2019;20:433.PubMedCentral Jalanka J, Major G, Murray K, et al. The Effect of psyllium husk on intestinal microbiota in constipated patients and healthy controls. Int J Mol Sci. 2019;20:433.PubMedCentral
39.
Zurück zum Zitat Zhai S, Zhu L, Qin S, et al. Effect of lactulose intervention on gut microbiota and short chain fatty acid composition of C57BL/6J mice. MicrobiologyOpen. 2018;7:e00612.PubMedPubMedCentral Zhai S, Zhu L, Qin S, et al. Effect of lactulose intervention on gut microbiota and short chain fatty acid composition of C57BL/6J mice. MicrobiologyOpen. 2018;7:e00612.PubMedPubMedCentral
40.
Zurück zum Zitat Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27-32.PubMed Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27-32.PubMed
41.
Zurück zum Zitat de la Coba Ortiz C, Arguelles Arias F, de Prados MDAC, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enfermed Dig. 2016;108:207–24. de la Coba Ortiz C, Arguelles Arias F, de Prados MDAC, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enfermed Dig. 2016;108:207–24.
42.
Zurück zum Zitat Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109:386–99.PubMed Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109:386–99.PubMed
43.
Zurück zum Zitat Lue A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. World J Gastroenterol. 2016;22:10477–81.PubMedPubMedCentral Lue A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. World J Gastroenterol. 2016;22:10477–81.PubMedPubMedCentral
Metadaten
Titel
Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing
verfasst von
Gemma Ibáñez-Sanz
Núria Milà
Luisa C. de la Peña-Negro
Montse Garcia
Carmen Vidal
Lorena Rodríguez-Alonso
Gemma Binefa
Francisco Rodríguez-Moranta
Victor Moreno
Publikationsdatum
07.11.2020
Verlag
Springer Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 1/2021
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01738-z

Weitere Artikel der Ausgabe 1/2021

Journal of Gastroenterology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.